Fantastic thinking. FTO inhibitors must factor into many different tumours.
Would I be right in thinking that once effective clinical trials are complete, the team would surely expand their pre-clinical testing against other cell types? Or would this usually occur after a massive capital injection / after M&A?
Pillar 1 - FTO (new thread), page-410
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $273.5M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.66 | $1.61 | $159.4K | 98.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5684 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |